
Fennec Pharmaceuticals Inc.: updates and filings
Price
$13.45
November 19, 2026Market cap $464M
What Ploutos Investor adds for Fennec Pharmaceuticals
Part of Ploutos Investor, €9.99 a month
- The full history: 14 fiscal years, from 2011
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has risen 22% since Nov 12, 2026, when the 10-Q these figures come from was filed ($10.90 then, $13.33 on Nov 18, 2026). The figures date from before that move.10-Q
- The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
Next results
last Mar 24, 2026next Feb 12, 2027
An estimate from when it has reported before, which has been regular. The company announces the date itself.
September 2026
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 12, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 19, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Sep 17, 2026Other material eventsForm8-K
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 13, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 13, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Jun 11, 2026Shares registered for employeesFormS-8
- Jun 10, 2026Shareholder voteForm8-K
- May 22, 2026Other material eventsForm8-K
- May 18, 2026Officer or director changeForm8-K
- May 15, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- May 14, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- May 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Apr 28, 2026Officer or director changeForm8-K
- Apr 28, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Apr 28, 2026Annual meeting proxy statementFormDEF 14A
- Apr 22, 2026Other material eventsForm8-K
- Apr 7, 2026Other material eventsForm8-K
- Mar 27, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Mar 24, 2026Results of operationsForm8-K
- Mar 16, 2026Other material eventsForm8-K
- Mar 5, 2026Shares registered for employeesFormS-8
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 12, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 19, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Sep 17, 2026 | 8-K | Other material events | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 13, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 13, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Jun 11, 2026 | S-8 | Shares registered for employees | Document |
| Jun 10, 2026 | 8-K | Shareholder vote | Document |
| May 22, 2026 | 8-K | Other material events | Document |
| May 18, 2026 | 8-K | Officer or director change | Document |
| May 15, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| May 14, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| May 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Apr 28, 2026 | 8-K | Officer or director change | Document |
| Apr 28, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Apr 28, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 22, 2026 | 8-K | Other material events | Document |
| Apr 7, 2026 | 8-K | Other material events | Document |
| Mar 27, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Mar 24, 2026 | 8-K | Results of operations | Document |
| Mar 16, 2026 | 8-K | Other material events | Document |
| Mar 5, 2026 | S-8 | Shares registered for employees | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Dec 10, 2002.
The full analysis
What do Fennec Pharmaceuticals's filings show?
The filings are where every one of Fennec Pharmaceuticals's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.